ErbB2 is a ligand-less member of the ErbB receptor family that functions as a coreceptor with EGFR, ErbB3, and ErbB4. Here, we describe an approach to target ErbB2's role as a coreceptor using a monoclonal antibody, 2C4, which sterically hinders ErbB2's recruitment into ErbB ligand complexes. Inhibition of ligand-dependent ErbB2 signaling by 2C4 occurs in both low-and high-ErbB2-expressing systems. Since the ErbB3 receptor contains an inactive tyrosine kinase domain, 2C4 is very effective in blocking heregulin-mediated ErbB3-ErbB2 signaling. We demonstrate that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment.
Introduction
pression is the outcome of a specific molecular alteration, i.e., ErbB2 gene amplification that results in excess protein synthesis The ErbB or HER signaling network is a receptor-ligand system (Slamon et al., 1987) . The accumulation of excess ErbB2 at the that is composed of four receptors and at least eleven ligands plasma membrane results in constitutive receptor activation due (Yarden and Sliwkowski, 2001) . In general, receptor expression to receptor self-association. Constitutive ErbB2 signaling is occurs in the epithelium, whereas ligands are produced in the thought to drive tumor growth. The availability of ErbB2 at the mesenchyme. Since these ligands are synthesized as memtumor cell surface allows the receptor to be targeted by trastuzubrane bound proforms, ligand processing and release are tightly mab. Although a number of explanations have been put forward regulated processes. In any particular tissue the receptors are to help explain trastuzumab's clinical benefit, the precise mechrarely, if ever, expressed alone, and as a result ErbB2 is freanism of action in any particular patient is still not completely defined. At present two primary mechanisms are thought to quently activated due to its role as a common coreceptor. An interesting feature of the ErbB system is that it is frequently account for trastuzumab's clinical benefit . The first is strictly biological and requires engagement coopted by various hyperproliferative diseases including cancer (Shawver et al., 2002) , psoriasis (Ben-Bassat and Klein, 2000) , of ErbB2 receptors with the bivalent antibody, which, in turn, results in receptor downmodulation and inhibition of aberrant and vascular restenosis (Kalmes et al., 2000) . As a result, two of these receptors, EGFR and ErbB2, are targets for drug devel-receptor tyrosine kinase signaling. A second mechanism of action is thought to occur from the interaction of trastuzumab's opment particularly in a number of solid tumors (Arteaga, 2001) . One example is trastuzumab (Herceptin), a humanized variant human Fc region with immune effector cells (Clynes et al., 2000) . Regardless of whether either or both of these mechanisms are of the 4D5 monoclonal antibody directed against ErbB2, which is overexpressed in a subset of human breast cancers (Cobleigh needed for a meaningful clinical outcome, treatment response is strictly dependent on high ErbB2 expression in the tumor. Slamon et al., 2001) . In these cases, ErbB2 overex-
S I G N I F I C A N C E
The ErbB or HER receptor network is frequently dysregulated in a number of solid tumors. Breast cancers containing ErbB2 overexpression can be treated with the ErbB2 antibody, trastuzumab (Herceptin). However, trastuzumab is only effective against high-ErbB2-expressing tumors. In this report, we target ErbB2's role as a coreceptor with other ErbB family members using another monoclonal antibody, 2C4. In contrast to trastuzumab, 2C4 disrupts ErbB2's association with other ErbB receptors and inhibits ligand-stimulated signaling in tumor cells that express lower ErbB2 levels. Potential therapeutic benefit of 2C4 treatment does not require the antibody to contain an intact Fc region and is observed in human breast and prostate cancer models, which do not overexpress ErbB2. Humanization of 2C4 will allow for assessment of its potential clinical utility. alternative immunotherapy approach is taken with the closely related EGFR. Here, antibodies are selected to inhibit ligand binding and subsequent downstream receptor signaling (Mendelsohn and .
Disruption of EGFR signaling can also be accomplished with compounds that inhibit the intrinsic tyrosine kinase activity of the receptor (Woodburn, 1999) . In particular, quinazolines, such as ZD-1839 or CPI-358,774 , which compete with one of the kinase substrates, ATP, appear to be promising clinically because they exhibit the requisite specificity for EGFR, are orally bioavailable, and have been generally well-tolerated to date in clinical trials (Baselga and Averbuch, 2000; Hidalgo et al., 2001; Woodburn, 1999) .
A number of studies suggest that inappropriate liganddependent ErbB2 activation may play a major role in driving tumor growth or survival pathways (Tzahar and Yarden, 1998) . To further explore these observations, we utilize an antibody, 2C4, that targets ErbB2 and disrupts ligand activation. The primary focus of this investigation was on breast and prostate cancer lines that do not overtly overexpress ErbB2 and therefore would not be targets for therapeutic agents such as trastuzumab. We demonstrate that 2C4 is effective in suppressing the growth of a number of xenografted tumors that do not overexpress ErbB2.
Results

2C4 blocks the association of ErbB2 with ErbB3
Since ErbB3 lacks intrinsic tyrosine kinase activity, it is incapable of initiating productive signaling without interacting with another receptor tyrosine kinase. In most cases, this receptor is ErbB2 (Graus-Porta et al., 1997; Klapper et al., 1999) . We studied whether ErbB3-ErbB2 complexes exist on the plasma membrane in the absence of the ErbB3 ligand, HRG. To answer this question, cell lines expressing ErbB3 and ErbB2 were treated with HRG or control buffer. Cells were then lysed and immuno-ErbB3 in breast cancer cell lines that express normal/low and high ErbB2 precipitations were performed with an anti-ErbB2 antibody that levels recognizes the intracellular domain of ErbB2. The immunopre-A: MCF7 (top), which expresses ErbB3 and low or normal levels of ErbB2, cipitates were then subjected to SDS-PAGE and transferred to and SK-BR-3 (bottom), which expresses ErbB3 and overexpresses ErbB2 at a nitrocellulose membrane for Western blotting using an antihigh levels, were treated with HRG or control buffer. ErbB3 was found in ErbB3 monoclonal antibody. The cell lines used for these experi-ErbB2 immunoprecipitates only when MCF7 cells are treated with the ErbB3 ligand HRG. A similar result is obtained when immunoprecipitates are prements were MCF7, which expresses low or normal levels of pared from the high ErbB2-expressing cell line SK-BR-3. B: A model for the ErbB2, and SK-BR-3, which overexpresses ErbB2. As shown proposed mechanism of 2C4 activity. Figure 1A , ErbB3 is found in ErbB2 immunoprecipitates only when MCF7 cells are treated with the ErbB3 ligand HRG. A similar result is obtained when immunoprecipitates are prepared from the high-ErbB2-expressing cell line SK-BR3 ( Figure 1A ).
be therapeutically active in the treatment of metastatic breast These data suggest that the recruitment of ErbB2 to ErbB3 cancer patients whose tumors overexpress ErbB2, and 2C4, occurs in a HRG-dependent manner. Moreover, even in cell lines which has been shown to ablate HRG-mediated signaling (Lewis that overexpress ErbB2, such as SK-BR3, little or no preformed et al., 1996; . Crossblocking studies, as complexes can be detected. Thus, the formation of the ErbB3well as epitope-mapping studies, have shown that trastuzumab HRG-ErbB2 complex occurs sequentially, i.e., ErbB3 binds HRG and 2C4 bind to distinct epitopes on the extracellular domain and then, in a second reaction, ErbB2 is added to the complex. of the ErbB2 receptor (Fendly et al., 1990) . More recently, it Alternatively, ErbB2 and ErbB3 may form a transient complex was demonstrated that trastuzumab inhibits ErbB2 ectodomain in the absence of HRG but the association may be too weak cleavage by matrix metalloproteases, whereas 2C4 does not to allow detection of the receptor complex. HRG binding may (Molina et al., 2001) . As shown in Figure 1A , 2C4 is far more serve to stabilize the ErbB2-ErbB3 complex once it has formed. effective in disrupting ligand-mediated ErbB3-ErbB2 complex We then studied whether antibodies to the extracellular doformation than trastuzumab or a control antibody. It is notewormain of ErbB2 were capable of disrupting the formation of thy that the 2C4-mediated disruption of this receptor complex ErbB3-HRG-ErbB2 complexes. Two antibodies to ErbB2 were is independent of ErbB2 expression levels, in that it is effective in blocking receptor complex formation in both low-and high-used in these studies, trastuzumab, which has been shown to Whole cell lysates were immunoprecipitated as described in Figure 1 and then probed for anti-phosphotyrosine. C: HRG-or TGF␣-induced MAPK activation are inhibited by 2C4 but not by trastuzumab. D: HRG-dependent Akt activation is inhibited by 2C4 and not trastuzumab. E: Inhibition of 125 I-HRG binding by 2C4 or 2C4-Fab. F: Inhibition of ErbB3-ErbB2 tyrosine phosphorylation by 2C4 or 2C4-Fab. The phosphorylation signal at 180 kDa was quantified by densitometry as described previously (Lewis et al., 1996) .
ErbB2-expressing cell lines. Based on the data presented, a mab. To verify the identity of ErbB2, MCF7 cell lysates were model for the disruption of ligand-dependent ErbB2 signaling immunoprecipitated with antibodies directed to a cytoplasmic by 2C4 is proposed in Figure 1B . epitope of ErbB2, and immunoblots were probed for phosphotyrosine ( Figure 2B ). Consistent with the results shown in Figure  2A , 2C4 treatment blocks the appearance of a HRG-dependent 2C4 diminishes ligand-activated ErbB2 signaling phosphorylation signal of ErbB2, whereas trastuzumab does in breast cancer cell lines not. Since ErbB3 requires the association with ErbB2 to initiate signal A downstream target of ErbB2 activation is MAPK (Erk 1 transduction, we determined the effect of anti-ErbB2 monoand Erk 2). To assess the effect of anti-ErbB2 MAbs on MAPK clonal antibodies on receptor activation. The MCF7 breast canactivation, MCF7 cells were treated, as described above, and cer cell line was treated with HRG in the presence or absence MAPK activation was measured using a phospho-specific of anti-ErbB2 monoclonal antibodies. As shown in Figure 2A , MAPK antibody ( Figure 2C ). Cells treated with HRG or TGF␣ a number of tyrosine phosphorylated proteins are detected in show strong activation of MAPK. This activation is diminished whole-cell lysates of HRG-treated MCF7 cells. The prominent with 2C4 treatment and to a much lesser degree with trastuzuband at ‫081ف‬ kDa is known to be a mixture of ErbB3 and ErbB2 mab. These data suggest that ErbB2 association with either (Sadick et al., 1996; . The phosphoryla-ErbB3 or EGFR is critical for complete activation of signal transtion of these bands is blocked by 2C4 treatment. In contrast, little if any decrease was observed in cells treated with trastuzu-duction to MAPK. This conclusion is in accordance with previous reports demonstrating that ErbB2 is a potent activator of the effect of intact 2C4 or a Fab version of 2C4 on 125 I-HRG binding to MCF7 cells (Lewis et al., 1996) . Both versions of 2C4 are Ras/Raf/MAPK pathway (Marte et al., 1995; Pinkas-Kramarski et al., 1996a) . effective in blocking high-affinity 125 I-HRG binding. To further Due to the presence of six YXXM motifs, ErbB3 is a very characterize the requirement for bivalency, we measured the potent activator of the PI3 kinase cascade (Soltoff et al., 1994) .
ErbB2-ErbB3 tyrosine phosphorylation levels in the presence To address the effect of ErbB2 MAbs on PI3 kinase activation, or absence of 2C4 or the 2C4-Fab. As shown in Figure 2F , both we measured the activity of the downstream kinase Akt using 2C4 and the 2C4-Fab block the HRG-stimulated phosphorylaa synthetic fusion protein derived from GSK3␣/␤. As seen in tion of the ErbB2-ErbB3 complex. In this assay format, the Figure 2D , treatment of MCF7 cells with the ErbB3 ligand, HRG, 2C4-Fab is less potent than the intact antibody. A possible results in activation of Akt that is inhibited by the pretreatment explanation for this effect may be the increased avidity expected with 2C4, but not by pretreatment with trastuzumab.
for the intact, bivalent antibody in comparison to the monovalent To determine whether 2C4 must be bivalent in order to Fab fragment. prevent ErbB2's recruitment into HRG-ErbB3 complexes, we assessed the properties of a monovalent Fab version of 2C4.
2C4 inhibits the growth of human breast cancer cell lines only in the presence of ligand A characteristic of an ErbB3-ErbB2 complex is the formation of a high-affinity HRG binding site (Fitzpatrick et al., 1998; Sliw- The ability of 2C4 to inhibit the in vitro proliferation of low-ErbB2expressing breast tumor cells was studied. The expression of kowski et al., 1994). As shown in Figure 2E , we examined the ErbB2 and other ErbB receptors in these breast cancer cell lines was reported by deFazio et al. (2000) . As demonstrated in Figure  3 , 2C4 does not directly inhibit growth of MCF7 ( Figure 3A) , MDA-MB-134 ( Figure 3B ), T-47D ( Figure 3C ), or ZR-75-1 ( Figure  3D ) cells compared to untreated cells. However, when the cells are treated with the ErbB ligand HRG, there is significant growth stimulation (between 155% and 230% of control growth), which is inhibited in all cases by treatment with 2C4. Exposure of the cells to EGF resulted in modest growth induction, which was also inhibited by 2C4 in the MCF7, MDA-MB-134, and ZR-75-1 breast tumor cells.
2C4 inhibits the growth of low-and high-ErbB2expressing human breast cancer xenograft tumors
To further examine the effect of 2C4 treatment on tumor cell growth, animals with established BT474 (high-ErbB2) or MCF7 (low-ErbB2) breast cancer xenograft tumors were administered anti-ErbB2 antibodies. Growth inhibition was demonstrated in the high-ErbB2 xenografts with both trastuzumab and 2C4 compared with control-treated tumors (trastuzumab, 77% growth inhibition, p ϭ 0.004, n ϭ 6; 2C4, 80% growth inhibition, p ϭ 0.001, n ϭ 10; Figure 3E ). The results with trastuzumab are similar to those reported previously (Baselga et al., 1998) . In experiments not shown here, 2C4 also inhibits the growth of several ErbB2 overexpressing tumor xenograft models including MCF7 cells transfected to overexpress ErbB2, MDA-MB-361 (which displays moderate or 2ϩ ErbB2 overexpression), and the lung adenocarcinoma cell line, CALU-3. We conclude that 2C4 shares trastuzumab's (or 4D5's) inhibitory activity toward models in which tumor growth is driven by ligand-independent ErbB2 activation. As expected (Pegram et al., 1999) , trastuzu- Figure 3F ). culture growth to the addition of 2C4 with and without rHRG␤1 or EGF is shown. Results are shown as percentage of control cell proliferation.
2C4 diminishes ligand-activated ErbB2 signaling in both androgen-dependent and -independent prostate cancer cell lines
Akt. As seen in Figure 4A , similar to the MCF7 cells, treatment A number of studies suggest that ErbB receptor activation may of both 22v1 and 22Rv1 cells with the ErbB3 ligand, HRG, results be important in the growth and survival of both androgenin activation of Akt that is inhibited by treatment with 2C4. dependent and androgen-independent prostate cancer (Agus The ability of 2C4 to inhibit the in vitro proliferation of the et al., Kim et al., 1999) . Therefore, 2C4 was evaluated in 22Rv1 (androgen-independent) cell line was studied. As demonboth in vitro and in vivo prostate cancer models. Similar to strated in Figure 4B , 2C4 does not inhibit growth of 22Rv1 cells the experiments using breast cancer cell lines, HRG-activated compared with untreated cells (p ϭ 0.86). However, when cells receptor phosphorylation levels were significantly decreased in are treated with HRG or EGF, there is significant growth inducprostate cancer cells that were pretreated with 2C4 in both tion (172% and 153% of control for HRG and EGF, respectively) the androgen-dependent (22v1) and androgen-independent (22Rv1) prostate cancer cell lines (data not shown). Neither of that can be inhibited by treatment with 2C4. these cell lines overexpress ErbB2. The effect of 2C4 treatment on MAPK activation in both the androgen-dependent and andro-2C4 inhibits the growth of both androgen-dependent and androgen-independent human prostate gen-independent prostate cancer cells was studied ( Figure 4A ).
Cells treated with HRG show strong activation of MAPK. This cancer xenografts
To determine if our in vitro observations translated into tumor activation is diminished with 2C4 treatment in both the androgen-dependent and androgen-independent strains. These data growth inhibition, we evaluated the efficacy of 2C4 on the growth of the androgen-independent prostate cancer xenograft CWR22R. suggest that ErbB2 association with ErbB3 is critical for complete activation of signal transduction to MAPK in prostate can-As shown in Figure 5A , three different versions of 2C4 were tested including the murine version (muMAb 2C4) and a fully cer cells, similar to the data described in the breast cancer experiments. The effect of ErbB2 MAbs on PI3 kinase activation humanized variant (rhuMAb 2C4) (C. Adams, D. Allison, J. Clark, B. Fan, T. Breece, C. Schmelzer, S. Brignoli, K. Totpal, G. Phil-was measured by studying the activity of the downstream kinase dent tumor. We conclude that the 2C4-mediated growth inhibition of the tumors was not through an immunologic mechanism, as intact Fc region was not required for tumor growth inhibition. The dose response relationship for CWR22R tumor growth inhibition by rhuMAb 2C4 is shown in Figure 5B . In this study, animals were administered a loading dose to more rapidly sustain rhuMAb 2C4 blood levels. Maximum growth inhibition was achieved with a loading dose of 60 mg/kg followed by weekly doses of 30 mg/kg. This dose response relationship is similar to that reported with trastuzumab and the ErbB2-transfected MCF7 cell line (Pietras et al., 1998) . The growth of a second androgen-independent model, CWRSA6 (Agus et al., 1999b) , was also examined for sensitivity to rhuMAb 2C4 ( Figure 5C ). As reported previously (Agus et al., 1999c) , trastuzumab had no effect on CWRSA6 tumor growth when compared to control (data not shown, p ϭ 0.63, n ϭ 10). In contrast, rhuMAb 2C4 demonstrated significant tumor growth inhibition relative to control-treated animals (CWRSA6, 82% growth inhibition, p ϭ 0.0047, n ϭ 10). To determine whether rhuMAb 2C4 also inhibited the growth of androgen-dependent prostate tumors, three different models were tested ( Figure 6 ). rhuMAb 2C4 demonstrated tumor growth inhibition in the androgen-dependent models of prostate cancer. At the doses and schedules tested, the degree of inhibition for trastuzumab (Agus et al., 1999c) and rhuMab 2C4 was similar. For trastuzumab (data not shown), growth inhibition observed with CWR22 was 68% (p ϭ 0.003, n ϭ 12), LNCaP was 89% growth inhibition (p ϭ 0.002, n ϭ 12), and LuCaP35 was 78% (p ϭ 0.002, n ϭ 12). rhuMAb 2C4 treatment demonstrated similar growth inhibition. With the CWR22 xenograft ( Figure 6A ), 93% growth inhibition was observed (p ϭ 0.0001); with LNCaP ( Figure 6B ), there was 83% growth inhibition (p ϭ 0.001); and with LuCaP35 ( Figure 6C ), there was 90% growth inhibition (p ϭ 0.001). None of the prostate cancer models used in this study overexpress ErbB2 in comparison to breast tumors with known ErbB2 gene amplification or breast cancer cell lines such as BT-474 or SK-BR-3 (Agus et al., 1999c) .
Expression of ErbB receptors and ligands in androgendependent and -independent tumor explants
Since the ErbB pathway is thought to be activated in the progression from androgen dependence to androgen independence (Craft et al., 1999; Scher et al., 1995) , we examined parental CWR22 and CWRSA6 to CWR22 was measured. A bearing animals were treated with an isotype control antibody (᭹); 6 mg/ summary of this analysis was made for the four ErbB receptors kg of rhuMAb 2C4 followed by two weekly injections at 3 mg/kg (᭺); 20 mg/kg of rhuMAb 2C4 followed by two weekly injections at 10 mg/kg (); and four ligands (Figure 7) . Interestingly, the androgen-indepenor 60 mg/kg of rhuMAb 2C4 followed by two weekly injections at 30 mg/ dent tumors appear to express higher levels of three EGFR kg ( ). C: CWRSA6 treated with rhuMAb 2C4 or trastuzumab, each adminisligands. Specifically, CWR22R expresses ‫-91ف‬fold and ‫-9ف‬fold tered at 20 mg/kg, twice per week.
higher levels of HB-EGF and TGF␣, respectively, relative to CWR22. In contrast, CWRSA6 expresses ‫-9ف‬fold and ‫-5ف‬fold levels of HB-EGF and EGF, respectively. lips, L. Presta, and M.X.S. unpublished data). In addition, we Discussion also tested a Fab version of rhuMAb 2C4 that was derivatized with polyethylene glycol (PEG-Fab) to allow for a longer serum
In previous reports, we investigated the role of ligand-activated half-life. In contrast to previous experiences with trastuzumab ErbB2 on the in vitro growth of various breast cancer cell lines (Kelley et al., 1992) Gene expression is plotted for the ratio of CWR22R/CWR22 and CWR22SA6/ CWR22. Assays were performed in triplicate and the average is shown.
gest that activation of the ErbB kinase axis results in androgen receptor activation (Kim et al., 1999) . Some of the molecular details defining these signal transduction pathways are beginning to emerge. For example, ErbB2 activation can lead to androgen target gene expression through activation of the MAPK pathway (Yeh et al., 1999) . More recently it has been reported that a constitutively active mutant form of ErbB2 leads to Akt activation and the androgen receptor is a substrate for Akt (Wen et al., 2000) . ErbB2 activation through Akt to the androgen receptor is proposed as a major pathway that promotes androgen-independent prostate cancer growth and survival. At present the mechanisms by which ErbB2 becomes activated in prostate cancer are unclear. Several reports suggested that ErbB2 gene amplification was common in prostate cancer (Kallakury et al., 1998; Ross et al., 1997) . However, a number of recent studies have failed to confirm these initial findings ( emergence of androgen independence. Experimental evidence for this possibility has been demonstrated by Craft et al. (1999) with the prostate cancer cell line LNCaP. Recently it was reextends these observations and further examines the role of ported that a similar phenomenon may occur in prostate cancer ligand-activated ErbB2 signaling in breast and prostate tumor patients (Osman et al., 2001; Shi et al., 2001; Signoretti et al., models. The developing and adult prostate is regulated by an-2000). drogen, a feature shared by most early forms of prostate cancer.
In the present study, we adopted an alternative strategy to Disease progression is the result of the emergence of an androtargeting ErbB receptors that is geared toward disrupting the gen-independent phenotype (Grossmann et al., 2001) . Although recruitment of ErbB2 into ErbB receptor-ligand complexes. The these tumor cells still express androgen receptor, the responramifications of our approach are dependent upon the particular siveness of the receptor to agonists or antagonists is frequently repertoire of ErbB receptors expressed by the tumor. In the altered. A number of recent studies have demonstrated that case of EGFR, which is fully functional as a tyrosine kinase, androgen receptor activation can also occur as a result of pepblocking the recruitment of ErbB2 into EGFR-ligand complexes does not ablate signaling but dampens the diversity, intensity, tide growth factor activation (Wells, 1999) . Several reports sug-and duration of signaling (Beerli and Hynes, 1996; growth in vivo suggest that biological activity is not dependent et al Karunagaran et al., 1996) . A number of biochemical on bivalency or the presence of an Fc region. To facilitate clinical and biological explanations have been put forward to help inteinvestigations in cancer patients, the pharmacokinetic and toxigrate the role that ErbB2 plays in complex with EGFR. Thus, in cological properties of an intact, humanized variant of 2C4 was comparison to when EGFR is expressed alone, the EGFR-ErbB2 examined in nonhuman primates (C. Adams, D. Allison, J. Clark, complex exhibits higher ligand affinities (Jones et al., 1999;  B. Fan, T. Breece, C. Schmelzer, S. Brignoli, K. Totpal, G. Phil-Karunagaran et al., 1996) , a more complex and diverse initiation lips, L. Presta, and M.X.S., unpublished data). The results of of signal transduction pathways (Olayioye et al., 1998; these preclinical studies suggest that rhuMAb 2C4 behaves very Kramarski et al., 1996b) , decreased rate of endocytosis (Worsimilar to trastuzumab with regard to pharmacokinetic properthylake et al., 1999), and altered receptor complex trafficking ties. Disrupting ligand-activated ErbB2 may complement other (Lenferink et al., 1998) . EGFR-ligand complexes containing strategies devised to target ErbB signaling in human neoplasms. ErbB2 exhibit a longer duration of signaling due to the fact that the complexes remain at the cell surface longer. Although a role (Beerli et al., 1994 (Beerli et al., , 1995 Guy et al., 1994) . The analysis 10% heat-inactivated FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin of clinical specimens derived from human tumors indicates that (GIBCO-BRL, Rockville, MD) and incubating at 37ЊC, 5% CO 2 , in a humidified the dynamic range of ErbB3 expression seems to be narrower atmosphere for 3-4 days to allow for cell attachment. Following the initial than that observed for either EGFR or ErbB2. A teleological incubation, the media was replaced with minimal essential medium conreason for this observation may be ErbB3's lack of tyrosine taining D-val (MEM D-val, ATCC, Manassas, VA) supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin kinase activity, which, if upregulated, would not convey a growth (GIBCO-BRL) . The CWR22/CWR22R cells were then allowed to grow for 4 advantage to the tumor because it lacks the ability to signal weeks or until only the epithelial cells remained. The MCF7, MDA-MB-134, autonomously. Instead, we hypothesize that inappropriate li-T47D, and ZR-75-1 breast tumor cell lines and 22Rv1 prostate carcinoma gand activation of ErbB3-ErbB2 signaling may play an important line were obtained from the American Type Culture Collection (Manassas, role in tumor growth. Support for this hypothesis lies in the VA) and used for proliferation studies. Cells were maintained in high-glucose observation that ErbB3 expressed together with ErbB2 is the DMEM:Ham's F-12 (50:50) supplemented with 10% heat-inactivated FBS most potent ErbB complex with regard to receptor signaling and 2 mM l-glutamine. For proliferation assays, cells were seeded into 96- (Pinkas-Kramarski et al., 1996a) . Moreover, the transformation well microtiter plates at a density of 10 4 cells per well and allowed to adhere potential of ErbB2-ErbB3 is also far greater than that observed overnight. The media were then replaced with low-serum media (1% FBS) Ϯ rhuMAb 2C4 at a concentration of 100-fold molar excess over ligand concen-for any other ErbB receptor complex (Alimandi et al., 1995;  tration (30 nM rhuMAb 2C4 for 22Rv1 and 300 nM for MCF7, MDA-134, Wallasch et al., 1995) . T47D, and ZR-75-1). The cells were allowed to sit at room temperature for Since ErbB2 functions as a coreceptor with other ErbB fam-2 hr, after which the ErbB ligands HRG-␤1 (0.3 nM) or EGF (3 nM for MCF7, ily members, overexpression of the receptor is not required 0.3 nM for 22Rv1) were added. Following a 3 day incubation, cell monolayers for signaling if ErbB ligands are available to drive biological were washed with PBS and stained with crystal violet dye for determination responses. Here we tested this notion directly using an antibody of relative cell proliferation as previously described (Lewis et al., 1996). directed against ErbB2 that appears to sterically block the asso-The xenograft studies were performed as previously described (Agus ciation of ErbB2 with other ErbB family members. Using this et al., 1999b, 1999c) . Four-to six-week-old nude athymic BALB/c male and approach, we demonstrate that ErbB2 activation may play a female mice were obtained from the National Cancer Institute-Frederick Cancer Center and maintained in pressurized ventilated caging at the Ce-critical role in driving the growth and survival of human breast dars-Sinai Medical Center vivarium. Male animals were inoculated subcuta-and prostate tumor xenografts. At present, we are uncertain neously with 1 ϫ 10 7 LNCaP cells or minced tumor tissue from the androgenabout several details regarding ErbB activation. Our failure to dependent CWR22 (gift from T. Pretlow) and LuCaP (gift from R. Vessela), detect 2C4 effects, in the absence of exogenous ligand addition, and females received the androgen-independent sublines CWR22R, on low-ErbB2-expressing cell lines derived from our tumor mod-CWRSA1, or CWRSA6, which were obtained by selecting tumors for reels suggests that the growth of these cell lines in vitro is not growth and increased serum PSA after androgen withdrawal (Agus et al., driven by autocrine production of ErbB ligands. A likely source 1999a). Female mice were inoculated with 1 ϫ 10 7 MCF7 cells. All lines of ligand production is the tumor stroma. Stroma-epithelial interwere injected together with reconstituted basement membrane (Matrigel; actions have been studied extensively with regard to breast and Collaborative Research, Bedford, MA), as described previously (Nagabhuprostate development (Chung, 1993; Cullen and Lippman, 1992; shan et al., 1996; Wainstein et al., 1994) . To maintain serum testosterone or estrogen (for the MCF-7 line) levels, mice were implanted with 12.5 mg Cunha, 1994) . Several ErbB ligands are known to be expressed sustained release testosterone pellets or 0.72 mg sustained release 17 in prostate and may be differentially expressed in prostate tu-␤-estradiol pellets (Innovative Research of America, Sarasota, FL) subcutamors (Scher et al., 1995; Adam et al., 1999; Duque et al., 2001;  neously before receiving the tumor cell inoculation. Treatments consisted of Torring et al., 2000) . We surmise that disrupting ErbB signaling twice weekly intraperitoneal injection of 20 mg/kg trastuzumab (Herceptin, by 2C4 may account for the inhibition of tumor growth.
rhuMAb ErbB2, trastuzumab, Genentech, Inc., South San Francisco, CA) or In conclusion, we demonstrate that an antibody, 2C4, di-2C4 (Genentech) in PBS for no less than 3 weeks. Control mice were given rected against ErbB2, disrupts its role as a coreceptor and vehicle alone. Tumors were measured every 3-4 days with vernier calipers, exhibits promising activity in models of breast and prostate and tumor volumes were calculated by the formula: /6 ϫ larger diameter ϫ cancer. The observations that monovalent versions of 2C4 are (smaller diameter) 2 . Animals with palpably established tumors of at least 65 mm 3 in volume were designated to treatment groups. also effective in blocking ErbB2 function in vitro and tumor MAP kinase (MAPK) and Akt assays using real-time quantitative PCR (TaqMan, ABI PRISM 7700, Applied Biosystems, Foster City, CA) technique, as previously described (Gibson et al., To assess MAPK phosphorylation, cells (10 5 /well) were plated in serumcontaining media in 12-well culture plates. The next day, media were re-1996; Heid et al., 1996) . The sequences of the primer/probe sets used for this analysis are as follows. F and R are the forward and reverse prim-moved and fresh media containing 0.1% serum were added to each well. This procedure was then repeated the following day, and prior to assay the ers, respectively, and P is the fluorescent-labeled probe. EGFR: (F) 5Ј-TTCCTGTGGATCCAGAGGA-3Ј, (R) 5Ј-AGCGTAATCCCAAGGATGT-3Ј, media were replaced with serum-free binding buffer (Jones et al., 1998) . Cells were allowed to equilibrate to room temperature and then incubated (P) 5Ј-FAM-AGGACGGACCTCCATGCCTTTGAGAA-TAMARA-p-3Ј; ErbB2/ neu: (F) 5Ј-TCTGGACGTGCCAGTGTGAA-3Ј, (R) 5Ј-TGCTCCCTGAGGACA for 30 min with 0.5 ml of 200 nM trastuzumab or 2C4. Cells were then treated with 1 nM EGF or TGF␣ or 0.2 nM rHRG␤1 177-244 (rHRG␤1) for 15 min. The CATCA-3Ј, (P) 5Ј-FAM-CAGAAGGCCAAGTCCGCAGAAGCC-TAMARA-p-3Ј; ErbB3: (F) 5Ј-TTCTCTACTCTACCATTGCCCAAC-3Ј, (R) 5Ј-CACCAC reaction was stopped by aspirating the cell medium and then adding 0.2 ml SDS-PAGE sample buffer containing 1% DTT. MAPK activation was TATCTCAGCATCTCGGTC-3Ј, (P) 5Ј-FAM-ACACCAACTCCAGCCACGCT CTGC-TAMARA-p-3Ј; ErbB4: (F) 5Ј-GAGATAACCAGCATTGAGCACAACassessed by Western blotting using an anti-active MAPK antibody (Promega, 3Ј, (R) 5Ј-AGAGGCAGGTAACGAAACTGATTA-3Ј, (P) 5Ј-FAM-CCTCTCC Madison, WI) as described previously (Jones et al., 1998) .
TTCCTGCGGTCTGTTCGA-TAMARA-p-3Ј; EGF: (F) 5Ј-AGCTAACCCAT For Akt activation, 10 cm dishes seeded the night before with 3 ϫ 10 6 TATGGCAACA-3Ј, (R) 5Ј-AGTTTTCACTGAGTCAGCTCCAT-3Ј, (P) 5Ј-FAMcells/dish were incubated for 3 hr in serum-free media. The cells were then AGGGCCCTGGACCCACCAC-TAMARA-p-3Ј; TGF␣: (F) 5Ј-GGACAGCACT incubated an additional hour in serum-free media containing either 2C4 or GCCAGAGA-3Ј, (R) 5Ј-CAGGTGATTACAGGCCAAGTAG-3Ј, (P) 5Ј-FAMtrastuzumab at a concentration of 100 nM, or in serum-free media without CCTGGGTGTGCCACAGACCTTC-TAMARA-p-3Ј; HRG: (F) 5Ј-TGGCTGAC additions (control). Ligand stimulation was carried out using 1 nM rHRG␤1 AGCAGGACTAAC-3Ј, (R) 5Ј-CTGGCCTGGATTTCTTC-3Ј, (P) 5Ј-FAM-CAG for 12 min. Akt activity was determined with an assay kit (Cell Signaling CAGGCCGCTTCTCGACAC-TAMARA-p-3Ј; HB-EGF: (F) 5Ј-GAAAGACTTC Technology) based on phosphorylation of GSK-3␣/␤. GSK-3 is a natural CATCTAGTCACAAAGA-3Ј, (R) 5Ј-GGGAGGCCCAATCCTAGA-3Ј, (P) 5Јsubstrate of the Akt kinase. Cell lysates were prepared and processed ac-FAM-TCCTTCGTCCCCAGTTGCCG-TAMARA-p-3Ј. cording to the kit manufacturer's directions. Briefly, immunoprecipitations Ribosomal protein 19 (RPL19) was used as a housekeeping gene for were performed on the cell lysates using an immobilized anti-Akt affinity gel.
EGFR family receptor genes. Primer/probe sets for RPL19 are (F) 5Ј-ATG The washed immunoprecipitates were then resuspended in a kinase buffer TATCACAGCCTGTACCTG-3Ј, (R) 5Ј-TTCTTGGTCTCTTCCTCCTTG-3Ј, and and incubated with a recombinant fusion protein that contains a portion of (P) 5Ј-FAM-AGGTCTAAGACCAAGGAAGCACGCAA-TAMRA-p-3Ј. the GSK-3␣/␤ sequence. Supernatants from these incubations were diluted ␤-actin was used as a housekeeping gene for the EGFR family ligands. in SDS-sample buffer, and phosphorylation of the fusion protein was as-Primer/probe sets for ␤-actin, listed here, were obtained from PE Applied sessed by Western blot using an antibody specific for phosphorylation of Biosystems (Foster City, CA): (F) 5Ј-TCACCCACACTGTGCCCATCTACGA-3Ј, GSK-3␣ at Ser21 or GSK-3␤ at Ser9.
(R) 5Ј-CAGCGGAACCGCTCATTGCCAATGG-3Ј, and (P) 5Ј-FAM-ATGCCCX (TAMARA)CCCCCATGCCATC-p-3Ј.
Immunoprecipitation
TaqMan analysis was performed in a standard 96-well plate format. The ability of ErbB3 to associate with ErbB2 was tested in a coimmunopreci-Standard curves were constructed using 3.9-1000 ng of total mRNA prepitation experiment. MCF-7 or SKBR-3 cells (10 6 cell/well) were seeded in pared from cultured cells of T47D for EGF and receptor genes and MDA-6-well tissue culture plates in 50:50 DMEM/Ham's F12 medium containing MB-231 for all other ligands and 31.25-500 ng for RPL19. Each dilution was 10% fetal bovine serum and 10 mM HEPES (pH 7.2) (growth medium) and run in duplicate. All samples were run in triplicate using 100 ng of mRNA allowed to attach overnight. The cells were starved for 2 hr in growth medium for each reaction. without serum prior to beginning the experiment. The cells were washed briefly with PBS and then incubated with either 100 nM of the indicated Statistical analysis of the xenograft experiments antibody diluted in 0.2% w/v BSA, RPMI medium, with 10 mM HEPES (pH Pairwise differences between the tumor volumes of the treatment groups 7.2) (binding buffer), or with binding buffer alone (control). After 1 hr at room were compared over time using a permutation test. The null hypothesis for temperature, rHRG␤1 was added to a final concentration of 5 nM to half this test is that treatment has no differential effect on the tumor volumes the wells and a similar volume of binding buffer was added to the other over time. The statistic (SS_Dev) used to test the hypothesis was the sum wells. The incubation was continued for approximately 10 min. Supernatants of the squared differences between mean tumor volume summed over all were removed by aspiration, and the cells were lysed in RPMI, 10 mM time points. This statistic reflects the amount by which the trajectories of HEPES (pH 7.2), 1.0% v/v Triton X-100, and 1.0% w/v CHAPS (lysis buffer) average tumor volume of the two treatment groups are different (Agus et containing 0.2 mM PMSF, 10 g/ml leupeptin, and 10 U/ml aprotinin. The al., 1999c). lysates were cleared of insoluble material by centrifugation.
ErbB2 was immunoprecipitated using a monoclonal antibody covalently Acknowledgments coupled to an affinity gel (Affi-Prep 10, Bio-Rad, Hercules, CA). This antibody (Ab-3, Oncogene Sciences, Boston, MA) recognizes a cytoplasmic domain
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Supernatants were run on 4%-12% polyacrylamide gels and electroblotted onto nitrocellulose membranes. The presence of ErbB3 was assessed by probing the blots with a polyclonal antibody against a cytoplasmic blots were visualized using a chemiluminescent substrate (ECL, Amersham Pharmacia Biotech, Piscataway, NJ). References
HRG binding assays
Adam, R.M., Borer, J.G., Williams, J., Eastham, J.A., Loughlin, K.R., and Assays to assess specific binding of 125 I-HRG were performed as described Freeman, M.R. (1999) . Amphiregulin is coordinately expressed with heparinpreviously (Lewis et al., 1996) .
binding epidermal growth factor-like growth factor in the interstitial smooth muscle of the human prostate. Endocrinology 140, 5866-5875. Real-time quantitative PCR RNA was prepared using RNeasy kits obtained from Qiagen (either maxi Agus, D.B., Cordon-Cardo, C., Fox, W., Drobnjak, M., Koff, A., Golde, D., and Scher, H.I. (1999a). Prostate cancer cell cycle regulators: response to 75161 or midi 75163, Qiagen, Valencia, CA). Gene expression was quantified
